| Protection by short-chain fatty acids against 1-beta-D-arabinofuranosylcytosine-induced intestinal lesions in germfree mice. | |
| | |
MedLine Citation:
|
PMID: 10103207 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In germfree mice, the administration of short-chain fatty acids (SCFA) protected the intestinal mucosa from damage produced by 1-beta-D-arabinofuranosylcytosine (Ara-C). Animals receiving SCFA and Ara-C had intestinal morphologies closer to normal than the control animals, which had severe intestinal lesions. We concluded that orally administrated SCFA reduce intestinal lesions, improving the mucosa pattern of the small intestine and colon. |
| | |
Authors:
|
M G Ramos; E A Bambirra; J R Nicoli; D C Cara; E C Vieira; J Alvarez-Leite |
Related Documents
:
|
8125387 - Effects of short chain fatty acids on gut morphology and function. 16289777 - Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simult... 7349487 - Effect of fermentable carbohydrates on volatile fatty acids, ammonia and mineral absorp... 18073277 - Use of phytogenic products as feed additives for swine and poultry. 7113547 - Influence of anti-rheumatic drugs on the activity of collagenolytic cathepsin in hepati... 10859157 - Identification and characterization of n-acetylcysteine conjugates of valproic acid in ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Antimicrobial agents and chemotherapy Volume: 43 ISSN: 0066-4804 ISO Abbreviation: Antimicrob. Agents Chemother. Publication Date: 1999 Apr |
Date Detail:
|
Created Date: 1999-06-03 Completed Date: 1999-06-03 Revised Date: 2013-04-17 |
Medline Journal Info:
|
Nlm Unique ID: 0315061 Medline TA: Antimicrob Agents Chemother Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 950-3 Citation Subset: IM |
Affiliation:
|
Departamento de Bioquímica e Imunologia, ICB-UFMG, Belo Horizonte, MG, Brazil. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Animals Cytarabine / adverse effects* Disease Models, Animal Fatty Acids, Volatile / adverse effects, therapeutic use* Fatty Liver / chemically induced Intestinal Diseases / chemically induced, pathology, prevention & control* Intestinal Mucosa / drug effects, pathology Mice Protective Agents / adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Fatty Acids, Volatile; 0/Protective Agents; 147-94-4/Cytarabine |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.
Next Document: Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical i...